Stockreport

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Corcept Therapeutics Incorporated  (CORT) 
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corcept.com/investors
PDF REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medic [Read more]